KEAP1 and cancer: The further investigation to find more potent derivatives from K‐563 or an investigation of the mechanism through which K‐563 exerts its activity is expected to lead to the development of anti‐cancer agents for Keap1‐ or Nrf2‐mutated cancer patients.